APA

Maio M., Scherpereel A., Calabrò L., Aerts J., Perez S. C., Bearz A., Nackaerts K., Fennell D. A., Kowalski D., Tsao A. S., Taylor P., Grosso F., Antonia S. J., Nowak A. K., Taboada M., Puglisi M., Stockman P. K. & Kindler H. L. (20170925). Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. : The Lancet. Oncology.

Chicago

Maio Michele, Scherpereel Arnaud, Calabrò Luana, Aerts Joachim, Perez Susana Cedres, Bearz Alessandra, Nackaerts Kristiaan, Fennell Dean A, Kowalski Dariusz, Tsao Anne S, Taylor Paul, Grosso Federica, Antonia Scott J, Nowak Anna K, Taboada Maria, Puglisi Martina, Stockman Paul K and Kindler Hedy L. 20170925. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. : The Lancet. Oncology.

Harvard

Maio M., Scherpereel A., Calabrò L., Aerts J., Perez S. C., Bearz A., Nackaerts K., Fennell D. A., Kowalski D., Tsao A. S., Taylor P., Grosso F., Antonia S. J., Nowak A. K., Taboada M., Puglisi M., Stockman P. K. and Kindler H. L. (20170925). Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. : The Lancet. Oncology.

MLA

Maio Michele, Scherpereel Arnaud, Calabrò Luana, Aerts Joachim, Perez Susana Cedres, Bearz Alessandra, Nackaerts Kristiaan, Fennell Dean A, Kowalski Dariusz, Tsao Anne S, Taylor Paul, Grosso Federica, Antonia Scott J, Nowak Anna K, Taboada Maria, Puglisi Martina, Stockman Paul K and Kindler Hedy L. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. : The Lancet. Oncology. 20170925.